NEWS Marie Liesse Le Corfec, Head of Global Portfolio Marketing at BD Pharmaceuti- cal Systems “BD is offering sup- port to COVID-19 drug and vaccine developers.” A s one of the largest global medicalin some of the world’s most critical technology companies in the world,vaccination campaigns, such as the our role in advancing the world ofSalk Polio vaccine trials, the Measles health has never beenclearer than it isInitiative in partnership with American today. BD is deploying our broad capa-Red Cross and the annual flu campaign bilities, expertise and scale to addressacross the globe. critical health needs related to corona- virus includingour diagnostic offeringsIn parallel,convenient prefilled formats to identify current or past exposure to willbe developed by the industry and SARS-CoV-2, real-time informatics andBD, reference supplier of prefillable electronic surveillance technology, andinjection devices for vaccines, is also essentialmedical devices to supportpreparing to support this effort. patient care. More generally, BD is offering support to Covid-19 drug and vaccine develop- This can also include anticipating theers to help accelerate time-to-market futuremass administration of Covid-19and support global health through a vaccines. As most of those vaccinesvariety of means. may be initially launched in vials, sy- ringes willbe needed for immunizationBD instruments, reagents and software campaigns. BD devices have been usedsolutions help researchers study immune